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Abstract: Hypoxic-ischaemic brain injury at birth is associated with 1–3/1000 cases of 
moderate  to  severe  encephalopathy.  Previously,  we  have  shown  that  connexin  43 
hemichannel blockade, with a specific mimetic peptide, reduced the occurrence of seizures, 
improved  recovery  of  EEG  power  and  sleep  state  cycling,  and  improved  cell  survival 
following global cerebral ischaemia. In the present study, we examined the dose response 
for intracerebroventricular mimetic peptide infusion (50 µmol/kg/h for 1 h, followed by  
50 µmol/kg/24 h (low dose) or 50 µmol/kg/h for 25 h (high dose) or vehicle only (control 
group), starting 90 min after the end of ischaemia), following global cerebral ischaemia, 
induced by 30 min bilateral carotid artery occlusion, in near-term fetal sheep (128 ±  1 days 
gestation).  Both  peptide  infusion  groups  were  associated  with  a  transient  significant 
increase in EEG power between 2–12 h after ischaemia. The ischaemia-low dose group 
showed  a  significant  recovery  of  EEG  power  from  day  five  compared  to  the  
ischaemia-vehicle and -high dose groups. In contrast, the high dose infusion was associated 
with  greater  secondary  increase  in  impedance  (brain  cell  swelling),  as  well  as  a  trend 
towards a greater increase in lactate concentration and mortality. These data suggest that 
higher doses of connexin mimetic peptide are not beneficial and may be associated with 
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adverse outcomes, most likely attributable to uncoupling of connexin 43  gap junctions 
leading to dysfunction of the astrocytic syncytium. 
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1. Introduction 
Hypoxia-ischaemia around the time of birth is associated with approximately 1–3/1000 cases of 
moderate to severe encephalopathy and a high risk of death or disability [1,2]. Hypoxia-ischaemia is 
characterized  by  progressive  evolution  of  damage  over  days  following  the  insult  [3,4].  The 
mechanisms underlying this striking spread of injury are not understood, although gap junctions are 
believed to contribute through a ―gap junction mediated bystander effect‖ [5,6]. Gap junctions are 
intercellular  channels  that  link  the  cytoplasm  of  adjacent  cells,  permitting  the  exchange  of  small 
molecules and ions. Non-specific, global gap junction blockers such as carbenoxolone, glycyrrhizic 
acid, heptanol and octanol are reported to provide neuroprotection in vitro [7,8], after stroke in adult 
rats [9] and in rat pups after intrauterine hypoxia-ischaemia [10]. However, this remains controversial 
with connexin 43 knockout mice showing greater injury following ischaemia compared to control 
animals [11]. In the brain, connexin 43 (Cx43) is the predominant astrocytic connexin and has been 
shown to be up-regulated in human post-mortem tissue and in near-term fetal sheep after cerebral 
ischaemia [12,13]. 
Evidence  now  implicates  astrocytic  connexin  hemichannels  in  the  propagation  of  injury. 
Hemichannels, or connexons, are half of the gap junction channel that sits in the unopposed membrane 
of a cell, prior to the formation of new channels. They are believed to remain closed under normal 
physiological  conditions  but  they  may  open  following  oxygen  glucose  deprivation,  metabolic 
inhibition or low extracellular calcium ion (Ca
2+) concentrations [14–18]. Hemichannel opening has 
been associated with disruption of the resting membrane potential, release of cytotoxic levels of ATP [19] 
and glutamate [20], and uptake of water resulting in cell swelling and rupture [21,22]. ATP has been 
implicated  in  neuropathic  pain  and  inflammation  [23],  and  in  spinal  cord  injuries  its  release  in 
peritraumatic areas causes excessive neuronal firing, followed by irreversible increases in intracellular 
Ca
2+ and cell death [24]. In cortical astrocytes these events are specifically Cx43 hemichannel related 
and  can  be  blocked  with  La
3+  or  peptides  that  block  Cx43  hemichannels;  treatments  that  block 
pannexin channels have no effect [18]. 
We recently reported that prolonged blockade of connexin 43 hemichannels with a specific mimetic 
peptide (50 µmol/kg/h for 1 h, followed by 50 µmol/kg/24 h), significantly improved neurological 
outcomes in the near-term fetal sheep following 30 min of cerebral ischaemia [13]. This included a 
reduction  in  seizures  and  the  incidence  of  status  epilepticus,  improved  recovery  of 
electroencephalogram (EEG) power and sleep state cycling and improved survival of oligodendrocytes 
with  intermediate  neuronal  survival  between  sham  controls  and  vehicle  treated  animals  [13].  
In contrast, infusion of a mimetic peptide of the same size that does not block hemichannels in vitro 
had no significant effect compared to ischaemia-vehicle infusion. The turnover of CSF is much faster 
in the near-term fetus than in adults [25], and permeability of the CSF-brain barrier is maximal in the Int. J. Mol. Sci. 2012, 13  6305 
 
 
first few hours immediately after ischaemia, and then decreases [26]. We therefore hypothesised that 
uptake of peptide would be reduced over time after ischaemia, and that a relatively large ongoing rate 
of peptide delivery would be needed to maintain stable ECF levels in the brain during the secondary 
phase of brain injury.  
Thus, in the present study we aimed to evaluate a log-order dose response curve for connexin 
mimetic  peptides  in  the  chronically  instrumented  near-term  fetal  sheep  at  0.85  gestation.  Brain 
maturation  at  this  age  in  the  sheep  is  equivalent  to  the  human  infant  at  term  [27,28].  This  well 
characterized  paradigm  allows  long-term,  real-time  monitoring  of  many  physiological  parameters 
including brain activity and temperature, carotid artery blood flow, heart rate, blood pressure and body 
movements [4,29]. The primary outcome of the present study was recovery of EEG power. Clinically, 
there is considerable evidence that greater recovery of EEG activity after perinatal hypoxia-ischaemia 
is associated with better neurodevelopmental recovery [30,31], and in the fetal sheep that EEG power 
is correlated with neuronal survival [4,13]. 
2. Results and Discussion 
2.1. Biochemistry and Survival 
There were no significant differences in baseline blood gas data, pH, glucose and lactate between 
groups  (Table  1).  Glucose  concentrations  were  significantly  elevated  from  baseline  in  the  
ischaemia-vehicle and -low dose groups between two hours and one day after ischaemia (p < 0.05).  
In the ischaemia-high dose group glucose levels were only significantly elevated from baseline at day 
one (p < 0.05). There was a significant increase in lactate concentrations after ischaemia in all groups 
at day one (p < 0.05), which was not significantly different between groups. A significant reduction in 
PaO2 was seen in the ischaemia-high dose group at day one (p < 0.05). 
All animals in the ischaemia-vehicle and -low dose groups survived the occlusion and recovery 
periods (7/7 and 6/6 respectively). In the ischaemia-high dose group all animals survived the occlusion 
period but two animals died between days two and three after ischaemia (2/7). Both of the animals that 
died had very high plasma lactate concentrations at day one (18.5 and 20.8 mmol/L) and at day two 
(8.11 and 11.9 mmol/L) before death. A third fetus developed an elevated lactate level at day one  
(11.2 mmol/L) but this resolved by day two (0.9 mmol/L).  
Table 1. pH, blood gas, lactate and glucose data before and two, four and six hours after  
30 min of global cerebral ischaemia, followed by a daily sample until day seven in the  
ischaemia-vehicle, -low and -high dose groups.  
pH  Baseline  2 h  4 h  6 h  1 day  2 day  7day 
Ischaemia-
vehicle  7.40 ±  0.01  7.39 ±  0.01  7.41 ±  0.01  7.40 ±  0.01  7.375 ±  0.02  7.39 ±  0.01  7.36 ±  0.01 
Ischaemia-low  7.40 ±  0.01  7.40 ±  0.01  7.41 ±  0.01  7.41 ±  0.01  7.38 ±  0.02  7.38 ±  0.01  7.35 ±  0.01 * 
Ischaemia-high  7.40 ±  0.01  7.40 ±  0.01  7.42 ±  0.01  7.41 ±  0.01  7.31 ± 0.05 †  7.39 ±  0.01  7.35 ±  0.00 Int. J. Mol. Sci. 2012, 13  6306 
 
 
Table 1. Cont. 
PCO2 (mmHg)  Baseline  2 h  4 h  6 h  1 day  2 day  7 day 
Ischaemia-
vehicle  44.6 ±  1.4  42.6 ±  1.6  43.4 ±  1.4  44.9 ±  1.9  44.4 ±  2.7  44.13 ±  1.3  49.4 ± 1.9 † 
Ischaemia-low  45.1 ±  1.7  44.8 ±  1.2  44.8 ±  1.6  46.6 ±  1.4  44.3 ±  1.4  42.73 ±  1.7  46.2 ±  1.4 
Ischaemia-high  46.6 ±  0.9  45.2 ±  1.1  45.5 ±  0.7  46.3 ±  0.9  45.3 ±  0.6  47.98 ±  1.6  48.7 ±  2.1 
PO2 (mmHg)  Baseline  2 h  4 h  6 h  1 day *  2 day  7 day 
Ischaemia-
vehicle  26.0 ±  1.1  25.8 ±  1.2  25.9 ±  1.25  25.4 ±  1.9  25.0 ±  2.0  24.6 ± 1.5†  23.0 ± 1.1 † 
Ischaemia-low  23.5 ±  0.9  22.9 ±  0.9  25.2 ±  1.48  24.6 ±  0.5  22.1 ±  1.5  23.4 ±  0.9  22.7 ±  1.0 
Ischaemia-high  20.7 ±  1.0  21.4 ±  1.0  22.9 ±  1.45  21.2 ±  1.5  18.0 ±  1.2  18.8 ±  2.6  21.6 ±  2.5 
Lactate 
(mmol/L)  Baseline  2 h  4 h  6 h  1 day  2 day  7 day 
Ischaemia-
vehicle  1.1 ±  0.1  2.4 ±  0.5  2.3 ±  0.5  2.0 ±  0.4  4.7 ± 1.1 †  0.94 ±  0.1  1.2 ±  0.1 
Ischaemia-low  1.1 ±  0.1  2.1 ±  0.3  2.0 ±  0.2  1.6 ±  0.2  2.3 ± 0.5 †  1.46 ±  0.2  1.1 ±  0.0 
Ischaemia-high  1.2 ±  0.1  2.4 ±  0.3  2.1 ±  0.2  1.9 ±  0.2  10.2 ± 3.3 †  4.21 ±  1.9  1.1 ±  0.1 
Glucose 
(mmol/L)  Baseline  2 h  4 h  6 h  1 day  2 day  7 day 
Ischaemia-
vehicle  0.9 ±  0.1  1.3 ± 0.1 †  1.3 ± 0.1 †  1.3 ± 0.1†  1.5 ± 0.1 †  0.9 ±  0.1  1.0 ±  0.1 
Ischaemia-low  0.8 ±  0.1  1.3 ± 0.1 †  1.2 ± 0.1 †  1.2 ± 0.1†  1.1 ± 0.1 †  1.0 ±  0.1  0.9 ±  0.1 
Ischaemia-high  0.8 ±  0.1  1.0 ±  0.1  1.0 ±  0.1  0.9 ±  0.1  1.4 ± 0.2 †  0.9 ±  0.1  0.8 ±  0.2 
Data are mean ±  SEM, * p < 0.05 ischaemia-vehicle vs ischaemia-high dose, † p < 0.05 vs baseline. For 
brevity days 3–6 have been omitted from this table as no significant differences occurred. 
2.2. Brain Activity and Impedance 
There  were  no  significant  differences  in  absolute  baseline  EEG  power  between  groups  
(ischaemia-vehicle 22.3 ±  1.3 vs. ischaemia-low dose 19.8 ±  3.1 vs. ischaemia-high dose 20.9 ±  1.1 dB). 
Cerebral  ischaemia  was  associated  with  rapid,  profound  suppression  of  EEG  power  in  all  groups 
(Figure 1), with no significant difference in EEG power during ischaemia. After release of occlusion, 
EEG activity gradually increased from its nadir, but remained suppressed compared to baseline for 
approximately eight hours in the ischaemia-vehicle group and then increased simultaneously with the 
onset of a period of intense seizure activity that lasted until approximately 48 h after ischaemia. In both 
of  the  groups  that  received  peptide,  EEG  power  was  significantly  higher  between  2–12  h  after 
ischaemia compared to the ischaemia-vehicle group (p < 0.05). There was no significant difference in 
the  time  of  seizure  onset  between  the  ischaemia-vehicle  (285  ±   63  min),  ischaemia-low  dose  
(258 ±  32 min) and ischaemia-high dose (373 ±  63 min) groups (p > 0.05). There was a weak inverse 
correlation between the average amplitude or total duration of seizures, during the peak period of  
22–26 h, with a peak lactate concentration at day one in the ischaemia-high dose group (r
2 = 0.37 and 
r
2 = 0.39, respectively). Following the resolution of seizures, total EEG power fell to below baseline 
levels in all groups. However, in the ischaemia-low dose group EEG power returned towards baseline Int. J. Mol. Sci. 2012, 13  6307 
 
 
and was significantly higher than the ischaemia-vehicle and-high dose groups from day five until the end 
of the experiment.  
Figure 1. EEG power shown as hourly averages from 12 h before until seven days after 
ischaemia (A), and five minute averages from two hours before until 12 h after ischaemia (B), 
in the ischaemia-vehicle, -low dose and -high dose groups, where peptide infusion was 
started 90 min after the end of ischaemia (the start of infusions is shown by the red arrow). 
Following the onset of occlusion, EEG power is rapidly suppressed in all three groups. A 
secondary rise in EEG power was seen in all groups, although this was significantly greater 
between 2–12 h in  the  ischaemia-low  and  -high dose  groups. This  was  followed by a 
reduction in EEG power to below baseline levels, which persisted at day seven. Data are 
mean ±  SEM. * p < 0.05. 
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The normal near-term fetal EEG characteristically shows sleep state cycling (Figure 2A). In the 
ischaemia-vehicle and-high dose groups EEG power remained reduced and no sleep state cycling was 
evident at day seven (Figure 2B, D). In contrast, in the ischaemia-low dose group EEG power was near 
baseline values and clear sleep state cycling was present (Figure 2C).  
There were no significant differences in baseline EEG spectral edge between groups (Figure 3). 
Ischaemia  was associated with  rapid  suppression of spectral  edge to  below baseline levels, which 
persisted to day seven in all groups. An apparent transient decrease in spectral edge was seen between 
48–72 h after occlusion in the ischaemia-high dose group, which was associated with data dropout due 
to the death of two fetuses. Int. J. Mol. Sci. 2012, 13  6308 
 
 
Figure 2. Examples of one minute averaged EEG data from individual fetal sheep showing  
(A)  the  typical  pattern  of  alternating  periods  of  low  and  high  amplitude  EEG  activity 
characteristic of sleep state cycling during the baseline period. (B–D) One minute averaged 
EEG  data  on  day  seven  in  the  ischaemia-vehicle  (B),  ischaemia-low  dose  (C)  and 
ischaemia-high  dose  (D)  groups,  with  clear  sleep  state  cycling  only  being  seen  in  the 
ischaemia-low dose group. 
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Figure 3. (A) Spectral edge was suppressed at the onset of occlusion and remained below 
baseline  in  all  groups.  (B)  Impedance  increased  during  occlusion  in  all  groups.  After 
release of occlusion, impedance returned towards baseline, followed by a secondary increase 
that was significantly greater in the ischaemia-high dose group. Data are mean ±  SEM,  
p < 0.05. 
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Cerebral  impedance  (a  measure  of  intracellular  oedema  [32])  increased  progressively  from 
approximately five minutes after the start of occlusion (Figure 3). There was no significant difference 
between  the  maximum  impedance  during  ischaemia  in  the  ischaemia -vehicle  (152.8  ±   3.7%), 
ischaemia-low dose (145.3 ±  5.5%) and ischaemia-high dose (154.8 ±  3.4%) groups (p > 0.05). After 
release  of  occlusion,  impedance  resolved  to  near  baseline  levels  over  30  to  45  min.  From 
approximately 18 h onwards a secondary rise in impedance developed in all groups, to a significantly 
greater  peak  in  the  ischaemia-high  dose  group  than  the  other  groups  (p  <  0.05).  By  day  seven, 
impedance had dropped below baseline in the ischaemia-vehicle and -high dose groups, whereas it 
appeared to remain at approximately baseline values in the ischaemia-low dose group (N.S.). 
2.3. Cardiovascular Parameters, Body Movements and Temperature 
In all groups, carotid artery occlusion was associated with a significant fall in carotid artery blood 
flow and an increase in fetal heart rate and mean arterial pressure compared to baseline (p < 0.05,  
Figure  4).  Following  the  release  of  the  occlusion  these  parameters  returned  to  baseline  values.  
A secondary rise in fetal heart rate, mean arterial pressure, nuchal electromyogram (EMG) and carotid 
blood flow was seen at approximately 18–36 h. There was no significant difference in any parameter Int. J. Mol. Sci. 2012, 13  6310 
 
 
between the groups. Extradural temperature was approximately 39.5 ° C, with a small diurnal fluctuation, 
with no significant difference between groups. 
Figure 4. There were no significant differences in nuchal EMG, mean arterial pressure, 
fetal  heart  rate,  carotid  artery  blood  flow  or  brain  temperature  between  the  
ischaemia-vehicle, -low dose and-high dose groups. Data are mean ±  SEM.  
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2.4. Discussion 
Consistent with our previous report, a low-dose dose mimetic peptide infusion started 90 min after 
reperfusion from severe cerebral ischaemia was associated with markedly improved recovery of EEG 
power  [13].  In  contrast,  high-dose  infusion  of  this  peptide  was  not  associated  with  any  apparent 
improvement  in  EEG  recovery,  but  instead  with  a  significantly  greater  secondary  rise  in  cerebral 
impedance (brain swelling), lower blood oxygen levels, and apparent trends to increased plasma lactate 
values and fetal death. Bilateral carotid artery occlusion is an exclusively cerebral insult, and although 
it is associated with severe neural injury, there is no systemic compromise [4,32]. 
There is increasing evidence to suggest that astrocytes play an important role in synaptic function. 
Astrocytes respond to the synaptic release of glutamate with an increase in intracellular Ca
2+ and can also 
modulate neuronal excitability via the release of neuroactive substances called gliotransmitters [33–35]. 
These gliotransmitters include glutamate, ATP, D-serine and tumour necrosis factor α [36–39]. Such 
research has led to the concept of the ―tripartite synapse‖, consisting of astrocytes along with the  
pre-  and  post-synaptic  terminals  [33].  This  has  been  shown  to  occur  when  an  astrocyte  releases 
glutamate that acts on both the pre- and post-synaptic terminals to modulate synaptic transmission and 
excitability  at  excitatory  and  inhibitory  synapses  [40–43].  Astrocytic  ATP  release  can  modulate 
excitability via purinergic receptors, whilst ATP that is degraded to adenosine can mediate depression 
of excitatory synapses [44,45]. It is possible that the early increase in EEG power seen in both the  
low- and high-dose peptide infusion groups was a result of reduced ATP release from astrocytes via 
connexin hemichannels. Intriguingly, this early increase in EEG power does not seem to have affected 
the longer-term recovery of EEG power, which was significantly improved after low-dose but not 
high-dose infusion. This is consistent with reports both in human infants and in large animals that EEG 
amplitude during the immediate recovery phase has relatively limited predictive value [46,47]. 
The relationship between hemichannel and gap junctional activity likely varies with the precise 
environmental  conditions.  In  cell  culture,  hypoxia  enhanced  connexin  hemichannel  opening  but 
reduced gap junction communication [18]. Conversely, Cotrina and colleagues have demonstrated that 
gap junction communication remains intact during ischaemia in brain slices  [37,48]. Physiological 
increases in Ca
2+ have been shown to inhibit gap junction permeability in HeLa cells [49]. Although 
intracellular  Ca
2+  levels  increase  rapidly  during  ischaemia  [50],  which  could  reduce  gap  junction 
coupling [49], after reperfusion, intracellular Ca
2+ concentration rapidly falls to baseline level, and is 
therefore unlikely to affect gap junction coupling in the latent phase. 
The  mechanism  of  loss  of  protection  with  high-dose  infusion  of  connexin  mimetic  peptide  is 
unknown, but it is highly likely to be related to blockade of the connexin 43 gap junctions in addition 
to connexin hemichannels. This is supported by evidence from O’Carroll et al., who showed loss of 
dye transfer between cells, when the same connexin mimetic peptide as used in this study was applied 
at 500 µM but not 5 µM doses [51]. In addition to the dose response, there may also be a time course 
response for mimetic peptide blockade of connexin hemichannels and gap junctions. Gap26, a mimetic 
peptide which binds to the first extracellular loop of connexin 43, has been shown to block connexin 43 
hemichannel  currents  in  less  than  five  minutes  in  single  cells  and  then  gap  junction  currents  after 
approximately 30 min in cell pairs, following application at a relatively high dose (175 µ M) [52,53]. 
However, that study did not test whether this sequence also occurred at lower doses. Indeed, low-dose Int. J. Mol. Sci. 2012, 13  6312 
 
 
Gap26 (0.5 µ M) applied either 10 min before or 30 min after the initiation of 40 min of myocardial 
ischaemia was shown to reduce myocardial infarct size by 48% and 55%, respectively, suggesting 
hemichannel  blockade  after  ischaemia  might  be  of  relatively  greater  importance  than  during  
ischaemia [54,55]. 
Although  transient  blockade  of  gap  junctions  following  ischaemia  or  injury  may  be  
beneficial [9,10,56], long-term blockade, such as that seen in the connexin 43 knockout mouse, has 
been associated with greater brain injury following ischaemia [11]. Thus, blockade of connexin 43 gap 
junctions  may  compromise  the  astrocytic  syncytium  and  impair  vital  functions.  These  functions 
include glutamate uptake from the extracellular space via the transporters GLT-1 and GLAST, and 
conversion of glutamate to glutamine which is then released for re-uptake by neurons [57]. Astrocytes 
are also responsible for spatial buffering of K
+, whereby uptake of K
+, cytosolic diffusion through the 
astrocytic syncytium, followed by release at a distant site, prevents ionic imbalances in active regions [58]. 
Extracellular K
+ under normal conditions is approximately 2.7–3.5 mM but can reach 50–80 mM 
during  ischaemia  and  sustained  exposure  can  trigger  death  in  fetal  rat  neuronal  cultures  through 
enhanced Na
+ entry into cells [59,60]. Astrocytes may also play a role in energy supply to neurons 
under  compromised  conditions  via  the  ―lactate  shuttle‖,  the  process  by  which  astrocytes  convert 
glycogen to glucose and glucose to lactate (as reviewed in [61]), which can then be transported to 
neurons and used for oxidative metabolism.  
The excessive rise in lactate concentration seen in three animals in the ischaemia-high dose group, 
despite no significant increase in seizure activity, may be due to impaired glucose trafficking through 
the astrocytic syncytium from the blood to the neurons. In turn this may result in astrocytes promoting 
greater  glycogenolysis  to  supply  lactate  as  a  fuel  for  local  neuronal  function.  Alternatively,  the 
decrease in  blood  PaO2 raises  the possibility that  the combination of seizure activity  with  greater 
background neural activity may have exceeded the capacity for oxidative metabolism, with lactate 
being generated from both neurons and astrocytes by anaerobic metabolism.The secondary increase in 
impedance, a measure of cytotoxic oedema [32], after brain ischaemia is a result of increased intracellular 
water uptake, predominantly in the glial cells of the grey matter [32,62,63]. Thus the present data suggest 
that high-dose infusion was associated with disruption of the astrocytic syncytium, which potentiated 
intracellular swelling, most likely through impaired local ion homoeostasis. 
In conclusion, this study suggests that while low dose infusion of a connexin 43 mimetic peptide 
that  blocks  gap  junction  hemichannel  opening  may  prove  to  be  a  clinically  useful  therapeutic 
intervention following perinatal ischaemia [13], higher doses may be associated with adverse effects 
on neural recovery and on survival, speculatively, by uncoupling gap junction communication within 
the astrocytic syncytium. 
3. Experimental Section  
3.1. Fetal Surgery 
All procedures were approved by the Animal Ethics Committee of The University of Auckland.  
In  brief,  20  time-mated  Romney/Suffolk  fetal  sheep  were  instrumented  using  sterile  technique  at  
118–124 days gestation (term is 145). Food, but not water was withdrawn 18 h before surgery. Ewes 
were  given  5  mL  of  Streptocin  (procaine  penicillin  (250,000  IU/mL)  and  dihydrostreptomycin  Int. J. Mol. Sci. 2012, 13  6313 
 
 
(250  mg/mL,  Stockguard  Labs  Ltd,  Hamilton,  New  Zealand))  intramuscularly  for  prophylaxis  
30 min prior to the start of surgery. Anesthesia was induced by I.V. injection of Alfaxan (Alphaxalone, 
3 mg/kg, Jurox, Rutherford, New South Wales, Australia), and general anesthesia maintained using  
2–3% isoflurane in O2. The depth of anesthesia, maternal heart rate and respiration were constantly 
monitored by trained anesthetic staff. Ewes received a constant infusion isotonic saline drip (at an 
infusion rate of approximately 250 mL/h) to maintain fluid balance. 
Following a maternal midline abdominal incision and exteriorization of the fetus, both fetal brachial 
arteries were catheterized with polyvinyl catheters to measure mean arterial blood pressure. An amniotic 
catheter was secured to the fetal shoulder. ECG electrodes (Cooner Wire Co., Chatsworth, California, USA) 
were sewn across the fetal chest to record fetal heart rate. The vertebral-occipital anastamoses were ligated 
and inflatable carotid occluder cuffs were placed around both carotid arteries [4,64]. A 3S Transonic 
ultrasonic flow probe (Transonic systems,  Ithaca, NY) was placed around the right carotid artery. 
Using a 7 stranded stainless steel wire (AS633-5SSF; Cooner Wire Co.), two pairs of EEG electrodes 
(AS633-5SSF; Cooner Wire Co.) were placed on the dura over the parasagittal parietal cortex (10 mm 
and 20 mm anterior to bregma and 10 mm lateral) and secured with cyanoacrylate glue. A reference 
electrode was sewn over the occiput. A further two electrodes were sewn in the nuchal muscle to 
record electromyographic activity as a measure of fetal movement and a reference electrode was sewn 
over the occiput. A thermistor was placed over the parasagittal dura 30 mm anterior to bregma. An 
intracerebroventricular catheter was placed into the left lateral ventricle (6 mm anterior and 4 mm 
lateral to bregma). The uterus was then closed and antibiotics (80 mg Gentamicin, Pharmacia and 
Upjohn,  Rydalmere,  New  South  Wales,  Australia)  were  administered  into  the  amniotic  sac.  The 
maternal laparotomy skin incision was infiltrated with a local analgesic, 10 mL 0.5% bupivacaine plus 
adrenaline (AstraZeneca Ltd., Auckland, New Zealand). All fetal catheters and leads were exteriorized 
through the maternal flank. The maternal long saphenous vein was catheterized to provide access for 
post-operative maternal care and euthanasia.  
3.2. Post-Operative Care 
Sheep were housed together in separate metabolic cages with access to food and water ad libitum. 
They were kept in a temperature-controlled room (16 ±  1 ° C, humidity 50 ±  10%), in a 12 h light/dark 
cycle. Antibiotics were administered daily for four days  I.V. to the ewe (600 mg Benzylpencillin 
Sodium, Novartis Ltd, Auckland, New Zealand, and 80 mg Gentamicin, Pharmacia and Upjohn). Fetal 
catheters were maintained patent by continuous infusion of heparinized saline (20 U/mL at 0.15 mL/h) 
and the maternal catheter maintained by daily flushing. 
3.3. Data Recording 
Data recordings began 24 h before the start of the experiment and continued for the remainder of 
the experiment. Data were recorded and saved continuously to disk for off-line analysis using custom 
data  acquisition  programs  (LabView  for  Windows,  National  Instruments,  Austin,  Texas,  USA). 
Arterial  blood  samples  were  taken  for  pre-ductal  pH,  blood  gas,  base  excess  (Ciba-Corning 
Diagnostics  845  blood  gas  analyser  and  co-oximeter,  Massachusetts,  USA),  glucose  and  lactate Int. J. Mol. Sci. 2012, 13  6314 
 
 
measurements (YSI model 2300, Yellow Springs, Ohio, USA). All fetuses had normal biochemical 
variables for their gestational ages [65,66]. 
3.4. Experimental Protocols 
Experiments  were  performed  at  128  ±   1  days  gestation.  Ischaemia  was  induced  by  reversible 
inflation of the carotid  occluder  cuffs with  saline for 30 min.  For Cx43 hemichannel  blocking, a 
peptide (H-Val-Asp-Cys-Phe-Leu-Ser-Arg-Pro-Thr-Glu-Lys-Thr-OH (Auspep, Vic, AU)) that mimics 
the  second  extracellular  loop  of  Cx43  (―Peptide  5‖  reported  in  [51])  was  infused  into  the  lateral 
ventricle via the intracerebroventricular catheter attached to an external pump. Control fetuses received 
cerebral ischaemia followed by infusion of the vehicle (ischaemia-vehicle, n = 7). The ischaemia-low 
dose group (n = 6) received 50 µmol/kg/h for one h followed by 50 µmol/kg/24 h for 24 h, and the 
ischaemia-high dose group (n = 6) received 50 µmol/kg/h for 25 h dissolved in artificial cerebrospinal 
fluid (aCSF), at a rate of 1 mL/h for 25 h starting 90 min after the end of the occlusion. Animals were 
killed at seven days with an overdose of sodium pentobarbitone (9 g I.V. to the ewe; Pentobarb 300, 
Chemstock International, Christchurch, N.Z.). 
3.5. Data Analysis 
Seizure activity was quantified as number, duration and peak amplitude of seizures between 22–26 h 
(time of peak EEG power) for each animal in the ischaemia-high dose group. This was correlated with 
lactate concentration at day one. The time of onset of the first seizure in each animal in both groups 
was determined. Seizures were defined as previously described by Scher et al. [67]. Seizures were 
visually defined on the  raw EEG recording as  sudden repetitive, evolving stereotyped waveforms 
lasting at least 10 seconds with an amplitude greater than 20 µV. Sleep state cycling was identified as 
alternating  periods  of  high  (non-rapid  eye  movement)  and  low  (rapid  eye  movement)  amplitude 
activity, with each period lasting approximately 20 min. Data was analyzed using ANOVA or repeated 
measures ANOVA, followed by the Tukey post-hoc test when a significant difference was found. 
Statistical significance was accepted when p < 0.05. 
4. Conclusions  
After  global  cerebral  ischaemia,  low  dose  mimetic  peptide  infusion  was  associated  with  an 
enhanced recovery of EEG power seven days after the insult, which was not seen with the high dose 
infusion. High dose mimetic peptide infusion was associated with a greater secondary increase in 
impedance, lower blood oxygen tension, and a trend towards a higher lactate concentration as well as 
greater  mortality  compared  to  animals  that  received  vehicle  infusion.  We  speculated  that  the 
deleterious effects seen with the high dose infusion were attributable to blockade or uncoupling of 
connexin 43 gap junctions in addition to hemichannels. 
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